FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileBiofrontera Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
BFRIW
Biofrontera Inc. Stock AnalysisComprehensive stock analysis for Biofrontera Inc. (BFRIW) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisBFRIW
BFRIW
Biofrontera Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
BFRIW
  1. Home
  2. Stocks
  3. Biofrontera Inc.

Biofrontera Inc.

🇺🇸BFRIW•NASDAQ

Biofrontera Inc.

🇺🇸BFRIW•NASDAQ
Market cap
$796.65K

Your view on BFRIW

Mkt Cap
$796.65K
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Biofrontera Inc.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
CEO
Hermann Luebbert
Headquarters
660 Main Street, Woburn, MA, US
Industry
Medical - Pharmaceuticals
Sector
Healthcare
CEO
Hermann Luebbert
Headquarters
660 Main Street, Woburn, MA, US
Description

Biofrontera Inc. is a biopharmaceutical firm specializing in the commercialization of pharmaceutical solutions for skin-related ailments across the United States. Its product lineup features Ameluz, a prescription drug employed with the BF-RhodoLED lamp series for photodynamic therapy.

This treatment is designed for both localized and broader area management of mild-to-moderate actinic keratosis on the face and scalp. Additionally, the company offers Xepi, a topical, non-fluorinated quinolone that functions by inhibiting bacterial growth to treat impetigo.

Established in 2015, Biofrontera Inc. is headquartered in Woburn, Massachusetts.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Biofrontera Inc.. Starting points for Biofrontera Inc.: EPS -$0.40, beta 0.80 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Biofrontera Inc.. Trailing twelve-month EPS for Biofrontera Inc. stands at -$0.40. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026
More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$0.24−$0.01−$0.39$0.20
Lowest estimate$0.23−$0.01−$0.39$0.20
Highest estimate$0.24−$0.01−$0.39$0.20
Number of analysts1111
A year ago$0.481−$0.411−$0.901—
Growth vs a year ago————

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$15.80M$11.00M$46.15M$53.47M
Lowest estimate$15.80M$11.00M$45.89M$53.30M
Highest estimate$15.80M$11.00M$46.40M$53.65M
Number of analysts2122
A year ago$17.10M$10.08M$41.70M—
Growth vs a year ago−7.6%+9.1%+10.6%—

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Biofrontera Inc.. Biofrontera Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold BFRIW17 companies
Compare BFRIW with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
ADILAdial Pharmaceuticals, Inc.HealthcareBiotechnology$13.3M
HCWBHCW Biologics Inc.HealthcareBiotechnology$260,418
LUCYInnovative Eyewear, Inc.HealthcareMedical - Instruments & Supplies$6.1M
SBFMSunshine Biopharma, Inc.HealthcareDrug Manufacturers - Specialty & Generic$4.7M
SNOASonoma Pharmaceuticals, Inc.HealthcareDrug Manufacturers - Specialty & Generic$3.7M
More Medical - Pharmaceuticals companies
TickerTypeCompanySectorExchangeMkt cap
QMDTQuick-Med Technologies, Inc.HealthcareOTC$11,204
RADLYRaia Drogasil S.A.HealthcareOTC$8.8B
RBIIRising BioSciences, Inc.HealthcareOTC$4,991
RCDTFRecordati Industria Chimica e Farmaceutica S.p.A.HealthcareOTC$11.6B
RGEDFGedeon Richter PLCHealthcareOTC$5.7B
RLLVFRelevium Technologies Inc.HealthcareOTC$2.0M
RMRKRimrock Gold Corp.HealthcareOTC$234,228
ROTHPharmaRoth Labs, Inc.HealthcareOTC$35,118
RPGLFRegent Pacific Group LimitedHealthcareOTC$36.5M
RPRXRoyalty Pharma plcHealthcareNASDAQ$30.5B
RSCIRedwood Scientific Technologies, Inc.HealthcareOTC$1,872
RTEZRest Ez Inc.HealthcareOTC$1.9B
Open Comparable Analysis
Ownership & News

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Biofrontera Inc. executives and directors. Shares of Biofrontera Inc. have traded between $0.02 and $0.10 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Biofrontera Inc.. Coverage tracks Biofrontera Inc. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Biofrontera Inc.

BFRIW AnalysisWeak
Past
1
Growth
1
Health
1
Profit
1
Value
1